BRIEF- GSK's Promacta/Revolade granted breakthrough therapy designation by FDA
February 03, 2014 at 05:41 AM EST
Feb 3 (Reuters) - GlaxoSmithKline Plc : * GSK gains FDA breakthrough therapy designation for Promacta/Revolade (eltrombopag) for severe aplastic anaemia * Designation based on results from study in 43 heavily pretreated patients
